首页 > 市场调查报告书 > 製药

消化器

胃肠病学市场规模、份额和成长分析（按类型、分销管道、应用、给药途径和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1898399

胃肠病学市场规模、份额和成长分析（按类型、分销管道、应用、给药途径和地区划分）—产业预测（2026-2033 年）

Gastroenterology Market Size, Share, and Growth Analysis, By Type (Branded, Generics), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Application, By Route Of Administration, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球胃肠病学市场规模将达到 396.1 亿美元，到 2025 年将成长至 419.4 亿美元，到 2033 年将成长至 663.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.9%。

胃肠道疾病盛行率的不断上升正在推动市场成长，这主要是由于不健康的饮食习惯和人口老化所造成的。可靠的临床研究数量激增和医疗保健支出不断增长也是重要的成长要素。目前，包括细胞疗法和创新小分子化合物在内的多种先进疗法已投入使用。胃肠道疾病导致的住院和手术干预增加进一步强化了这一趋势，促使生物製药公司加强对生物製剂和生物相似药的研发投入。该领域正在进行的临床试验为开发有效治疗方法提供了许多机会，为胃肠道医疗保健领域的变革性进步铺平了道路。

全球胃肠病学市场驱动因素

全球胃肠病学市场受到胆结石、溃疡性大肠炎、痔疮、大肠激躁症(IBS) 和胃食道逆流 (GERD) 等消化系统疾病日益普遍的显着影响。不健康的饮食习惯、久坐的生活方式、不断上升的压力水平、食物过敏和感染疾病等因素均导致慢性及急性胃肠道疾病发病率的上升。因此，对包括制酸剂、泻药、质子帮浦抑制剂和抗生素在内的各种药物的需求不断增长，这些药物旨在有效控制这些疾病并减少潜在的健康併发症。治疗需求的激增正在推动全球胃肠病学治疗市场的成长。

限制全球胃肠病学市场的因素

由于治疗费用高昂，全球胃肠病学市场可能面临严峻挑战。包括克隆氏症和溃疡性大肠炎等慢性疾病在内的多种胃肠道疾病需要持续管理，以降低復发风险和潜在的癌症进展。治疗的综合成本主要包括药物费用、医疗咨询费用和住院费用。慢性胃肠道疾病的治疗通常涉及生技药品的使用，而生物製剂价格昂贵。这些高昂的自付费用预计将严重阻碍市场成长，并影响许多寻求治疗的患者获得治疗的机会。

全球胃肠病学市场趋势

全球胃肠病市场正经历强劲成长，这主要得益于溃疡性大肠炎和克隆氏症多种胃肠道疾病盛行率的上升。需求的激增促使製药和生技公司优先投入研发，以开发新型疗法。这些公司不断扩充的研发管线表明，市场环境充满活力，专注于解决复杂的胃肠道疾病问题。随着相关人员加大对突破性疗法的投资，预计该市场将显着扩张。区域和全球供应商为开发最先进治疗而进行的合作，进一步加速了胃肠病治疗市场的成长。

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较
主要企业简介
- 艾伯维公司（美国）
- 武田药品工业株式会社（日本）
- 阿斯特捷利康有限公司（英国）
- 拜耳股份公司（德国）
- 辉瑞公司（美国）
- 强生公司（美国）
- 诺华公司（瑞士）
- 默克公司（美国）
- 赛诺菲公司（法国）
- 葛兰素史克有限公司（英国）
- 勃林格殷格翰国际有限公司（德国）
- 梯瓦製药工业股份有限公司（以色列）
- 波士顿科学公司（美国）
- 美敦力公司（爱尔兰）
- 奥林巴斯株式会社（日本）
- 富士软片株式会社（日本）
- 史赛克公司（美国）
- 雀巢健康科学（瑞士）
- 达能股份有限公司（法国）

结论与建议

简介目录

Product Code: SQSG35I2028

Global Gastroenterology Market size was valued at USD 39.61 Billion in 2024 and is poised to grow from USD 41.94 Billion in 2025 to USD 66.35 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The gastroenterology market is experiencing significant growth driven by the increasing prevalence of gastrointestinal diseases, largely attributed to unhealthy dietary habits and an aging population. Key growth factors include the surge in clinical studies yielding reliable results and escalating healthcare expenditures. There is a diverse array of advanced treatment options available, such as cellular therapies and innovative small molecules. The rise in hospitalizations and surgical interventions for gastrointestinal issues further underscores this trend, prompting biopharmaceutical firms to enhance their R&D investments in biologics and biosimilars. The ongoing clinical trials in the field present numerous opportunities for the development of effective therapies, paving the way for transformative advancements in gastroenterological care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroenterology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroenterology Market Segments Analysis

Global Gastroenterology Market is segmented by type, distribution channel, application, route of administration and region. Based on type, the market is segmented into branded and generics. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. Based on application, the market is segmented into crohn's disease, ulcerative colitis, Gerd, IBS and others. Based on route of administration, the market is segmented into injectable and oral & others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroenterology Market

The global gastroenterology market is significantly influenced by the increasing prevalence of gastrointestinal diseases, including conditions like gallstones, ulcerative colitis, hemorrhoids, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD). Factors such as unhealthy dietary habits, sedentary lifestyles, heightened stress levels, food sensitivities, and infections contribute to the rising incidence of both chronic and acute gastrointestinal disorders. As a result, there is a growing demand for a variety of medications, including antacids, laxatives, proton pump inhibitors, and antibiotics, aimed at effectively managing these conditions and mitigating potential health complications. This surge in treatment requirements is propelling the growth of the global therapeutics market for gastrointestinal diseases.

Restraints in the Global Gastroenterology Market

The Global Gastroenterology market is likely to encounter substantial challenges stemming from the high expenses associated with treatments. Various gastrointestinal disorders, particularly chronic conditions like Crohn's disease and ulcerative colitis, necessitate ongoing management to mitigate the risk of recurrence and potential cancer development. The comprehensive costs of therapy primarily consist of medication, healthcare provider consultations, and hospital admissions. Treatments for chronic gastrointestinal diseases often involve the administration of biologic medications, which can incur hefty expenses. These elevated out-of-pocket costs for drugs and medical procedures are expected to significantly hinder market growth, impacting accessibility for many patients seeking care.

Market Trends of the Global Gastroenterology Market

The global gastroenterology market is witnessing robust growth driven by an uptick in the prevalence of various gastrointestinal disorders, including ulcerative colitis and Crohn's disease. This surge in demand is prompting pharmaceutical and biotechnology companies to prioritize research and development efforts to innovate novel therapeutics. Enhanced pipeline expansion from these firms is indicative of a dynamic landscape focused on addressing complex gastrointestinal ailments. As stakeholders increasingly invest in groundbreaking treatments, the market is expected to experience significant expansion. The collaborative efforts of regional and global vendors in developing cutting-edge therapies are further propelling the trajectory of the gastroenterology therapeutics market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Gastroenterology Market Size by Type & CAGR (2026-2033)

Market Overview
Branded
Generics

Global Gastroenterology Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Global Gastroenterology Market Size by Application & CAGR (2026-2033)

Market Overview
Crohn's Disease
Ulcerative Colitis
Gerd
IBS
Others

Global Gastroenterology Market Size by Route Of Administration & CAGR (2026-2033)

Market Overview
Injectable
Oral & Others

Global Gastroenterology Market Size & CAGR (2026-2033)

North America (Type, Distribution Channel, Application, Route Of Administration)
- US
- Canada
Europe (Type, Distribution Channel, Application, Route Of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Distribution Channel, Application, Route Of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Distribution Channel, Application, Route Of Administration)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Distribution Channel, Application, Route Of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Limited (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stryker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle Health Science (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danone S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments